Rheumatology.net

Rheumatology Xagena

Search results for "Cosentyx"

Since the publication of the European League Against Rheumatism ( EULAR ) recommendations for the pharmacological treatment of psoriatic arthritis ( PsA ) in 2012, new evidence and new therapeutic age ...


Interleukin-17A ( IL-17A ) is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, Secukinumab ( Cosentyx ), a fully human anti-IL-17A monoclonal antibody ...


New data showing Secukinumab ( Cosentyx ) delivers sustained improvements in the signs and symptoms of psoriatic arthritis over three years, including patient-reported pain, were presented at the 2016 ...